Follow us on Twitter
twitter icon@FreshPatents

Malignant Cells patents

      

This page is updated frequently with new Malignant Cells-related patent applications.




 Cyclic peptide conjugates and methods of use patent thumbnailCyclic peptide conjugates and methods of use
The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).. .
Modulation Therapeutics


 Multiple target t cell receptor patent thumbnailMultiple target t cell receptor
The present invention is directed to a functional t cell receptor (tcr) fusion protein (tfp) recognizing and binding to at least one mhc-presented epitope, and containing at least one amino acid sequence recognizing and binding an antigen. The present invention is further directed to an isolated nucleic acid molecule encoding the same, a t cell expressing said tfp, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen..
Max-delbrück-centrum Für Molekulare Medizin


 Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells patent thumbnailCompounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
Methods are provided herein for use of e-selectin antagonists for mobilizing cells, such as hematopoietic cells, hematopoietic stem cells and progenitor cells, white blood cells, and malignant cells, and hematopoietic tumor cells from the bone marrow. More specifically, methods are provided for using e-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers, and peptides for mobilizing cells from the bone marrow to the peripheral vasculature and tissues..

 Novel n- and c-terminal substituted antagonistic analogs of gh-rh patent thumbnailNovel n- and c-terminal substituted antagonistic analogs of gh-rh
There is provided a novel series of synthetic analogs of hgh-rh(1-29)nh2 (seq id no: 1) and hgh-rh(1-30)nh2. Of particular interest are those carrying phac, n-me-aib, dca, ac-ada, fer, ac-amc, me-nh-sub, phac-ada, ac-ada-d-phe, ac-ada-phe, dca-ada, dca-amc, nac-ada, ada-ada, or ch3—(ch2)10—co-ada, at the n-terminus and β-ala, amc, apa, ada, ae2a, ae4p, ε-lys(α-nh2), agm, lys(oct) or ahx, at the c-terminus.
U.s.a., Represented By The Department Of Veterans Affairs


 Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells patent thumbnailPlatinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells
The subject invention concerns a compound and compositions having activity as an inhibitor of stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula i, formula ii, or formula iii.
University Of Central Florida Research Foundation, Inc.


 Cancer treatment methods using remote conditioning patent thumbnailCancer treatment methods using remote conditioning
Cancer treatment methods comprising a step of applying remote conditioning to the cancer subject, for example remote ischemic conditioning via several episodes of short-term limb occlusion. Upregulation and release of remote conditioning substances such as microrna 144/451 cluster endogenously caused by remote conditioning may be beneficial in reducing the growth and proliferation of malignant cells.
Lifecuff Technologies Inc.


 Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms patent thumbnailHalogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms
Halogenated aliphatic carboxylic acids, salts and/or oligomers or polymers thereof, which exhibit a devitalizing effect of neoplastic tissues, are disclosed. Methods and uses that utilize these compounds for the treatment of medical conditions associated with a neoplastic tissue are also disclosed.
Cimas Limited


 Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic sendai virus patent thumbnailMethod for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic sendai virus
The invention relates to the field of immunology and medicine, more specifically, oncology, and can be useful for the treatment of patients with carcinomas and sarcomas. A pharmaceutical composition is provided which contains biologically active oncolytic sendai virus strain moscow pta-13024, and a method of treating patients with said malignancies is developed including administration of the said composition to a patient's body.

 Expanded nk cells patent thumbnailExpanded nk cells
The present invention relates to expanded nk cells. The nk cells have been expanded ex vivo, are activated and have a cytotoxic phenotype.
Cellprotect Nordic Pharmaceuticals Ab


 Compositions and methods of use of phorbol esters patent thumbnailCompositions and methods of use of phorbol esters
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like hiv and aids, or the development of neoplasms in a mammalian subject.

Compositions and methods for cancer therapy


The invention provides compositions and methods to treat cancer with an agent that selectively promotes cancer cell death relative to non-malignant cells by mechanisms that include increased oxidative stress (“a therapeutic agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.. .
University Of Iowa Research Foundation


Targeted sensitization of non-del(5q) malignant cells


Disclosed are molecules for treating non-del(5q) mds that mimic allelic deficiency in del5q mds to sensitize the malignant clones of patient without del(5q). The disclosed molecule contains an inhibitor of cdc25c, an inhibitor of pp2acα, or a combination thereof, and a toll like receptor-9 (tlr9) targeting ligand.
H. Lee Moffitt Cancer Center And Research Institute, Inc.


Erbb-2 receptor targeting peptide


The erbb-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. Bacteriophage display technology was employed to identify peptides that bound to the extracellular domain of human erbb-2.
The Curators Of The University Of Missouri


Methods and compositions for screening and detecting biomarkers


The present invention is concerned with a novel antigens associated with human tumors, including carcinomas of the colon or lung, as well as novel monoclonal antibodies which specifically bind to said antigen. The antibodies bind to normal human cells to a much lesser degree than to tumor cells.
Edp Biotech Corporation


Methods and compositions for treatment of hematologic cancers


The present invention relates to oncolytic picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed picornavirus such as coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto grafts prior to transplantation..
Viralytics Limited


Oncolytic measles virus


The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein..

Compositions and methods of use of phorbol esters


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like hiv and aids, or the development of neoplasms in a mammalian subject.

Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens


The invention relates to recombinant yeasts of the kluyveromyces lactis species for the production of a humoral immune response against defined antigens, to the production of said yeasts, and to the use thereof for protective vaccination against pathogens and malignant cells containing said antigens.. .
Martin-luther-universitaet Halle-witterberg


Therapies for cancer using rlip76


The present invention is a composition identified as a region of rala binding protein 1, wherein the region neighbors a membrane-associated portion of the rala binding protein 1, reduces transport activity and membrane association of the rala binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells.
Board Of Regents, The University Of Texas System


S100 protein inhibitors for treating leukemia


The present invention relates to a compound, composition and method for reducing or inhibiting the differentiation or development of progenitor blood cells into malignant cells, leukemia cells or physiologically pathological cells. Particularly, the invention describes the use of inhibitors of s100 proteins, including myeloid related proteins.
Universite Laval


Method for ex-vivo purging in autologous transplantation


The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of fasl to kill malignant cells without substantially affecting viability of cells to be transplanted. Autologous stem cell transplantation (asct) following high-dose chemotherapy with or without radiotherapy has become the standard therapy for the majority of patients with large-cell lymphomas, multiple myeloma, and refractory/recidivating hodgkin's disease.
Topotarget Switzerland Sa


Inhibitors targeting the dna-binding domain of human stat3 for treatment of metastatic cancers


The present invention provides stat3 inhibitors which preferentially suppress proliferation of cancer over non-cancer cells and inhibit migration and invasion of malignant cells. The inhibitors of the present invention selectively inhibit stat3 binding to dna without affecting the activation and dimerization of stat3.

Method for detection of l523s expression in biological samples


The present invention discloses methods for differentiating between normal or reactive cells and malignant cells in biological samples comprising: exposing the biological sample to an antibody to l523s protein and detecting the presence of the antibody bound to l523s protein within the malignant cells, in embodiments, such methods may further comprise: exposing the biological sample to an antibody to a second protein that is a marker of cell lineage and detecting the presence of the antibody to the second protein within cells corresponding to a particular ceil lineage and/or may comprise: exposing the biological sample to an antibody to a third protein which is a marker of cells that are normal or reactive and detecting the presence of the antibody to the third protein within cells that are normal or reactive.. .
Dako Denmark A/s


Peptides for the treatment of cancer


The invention relates to novel cyclic compounds (cyclic peptides), linkers useful as beta-turn promoters in cyclic peptides, and methods for treatment of malignant cells in vitro or in vivo using one or more linear and cyclic peptides. The peptides can act as integrin interaction inhibitors and may be used in the treatment of cancers as monotherapies or in combination with other anti-cancer agents, such as proteasome inhibitors, inhibitors of autophagy, alkylating agents, mek inhibitors, fak/pyk2 inhibitors, and egfr inhibitors.
University Of South Florida


Method of treating a malignancy in a subject and a pharmaceutical composition for use in same


There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the picornaviridae family.
Viralytics Limited


Method for separating aggregates of malignant cells and aggregates from stromal cells of a malignant tumour tissue sample


An ex vivo malignant tumor tissue sample is cleaned, comminuted, suspended in culture medium, subjected to a treatment with collagenase and the collagenase decomposition product is centrifuged. The pellet obtained is re-suspended in culture medium by an absorption instrument, is absorbed and returned several times and transferred to a culture vessel.
Flacod Gmbh


Method for combined imaging and treating organs and tissues


The present invention provides methods and compositions for detecting and treating malignant tissue, organs or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus or by a route providing access to the tissue or organ, with a composition comprising a monoclonal antibody (chimeric, humanized, fully human), partial antibody, fab fragment, antibody fragment that is tagged with a fluorophore with or without the addition of a therapeutic chemotherapy molecule, which specifically binds to the targeted organ, tissue or cell.

High affinity t cell receptor and use thereof


The present invention is directed to a high affinity t cell receptor (tcr) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a t cell expressing said tcr, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.. .

Mammography-apparatus, paddle and measuring a contact area between a breast and the mammography-apparatus


Mammography-apparatus for detecting malignant cells in a breast, comprising an x-ray source and an x-ray detector that cooperates with the x-ray source for providing an x-ray image of said breast, and further comprising a paddle for flattening the breast by pressing it against said x-ray detector, and comprising a contact area measuring device for measuring a contact area between the breast and the paddle, wherein the contact area measuring device is embodied with at least a first laminate of an electrically insulating material and an electrically low resistance material, which first laminate is provided on a side of the paddle facing the breast, and wherein the electrically low resistance material is sandwiched between the paddle and the insulating material.. .

Small molecule inhibitors of stat3 with anti-tumor activity


The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s31-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.

Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies


Compositions including an antibody specific for cd44 are provided. These antibodies specifically bind to hematologic malignant cells.

Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells


The subject invention concerns a compound and compositions having activity as an inhibitor of stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula i, formula ii, or formula iii.

Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma


Methods and compositions are provided for treating human synovial sarcoma (ss). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma.

Treatment of proliferative disorders


The present invention relates to a method and composition for treating safely (in a non-toxic way) disease or disorder exhibiting excessive cellular proliferation comprising administering to a patient needing such treatment, a composition comprising curcumin (derived from turmeric), epigallocatechin-3-gallate (egcg, enriched in green tea), glucosinolates (enriched in cruciferous vegetables) and/or derivatives thereof, such as sulforaphane (sfn), alone or combined with a ketogenic diet or a modified ketogenic diet. Also the current invention relates to a composition comprising medium chain triglycerides, epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as sulforaphane (sfn).

Novel n- and c-terminal substituted antagonistic analogs of gh-rh


There is provided a novel series of synthetic analogs of hgh-rh(1-29)nh2 (seq id no: 1) and hgh-rh(1-30)nh2. Of particular interest are those carrying phac, n-me-aib, dca, ac-ada, fer, ac-amc, me-nh-sub, phac-ada, ac-ada-d-phe, ac-ada-phe, dca-ada, dca-amc, nac-ada, ada-ada, or ch3—(ch2)10—co-ada, at the n-terminus and β-ala, amc, apa, ada, ae2a, ae4p, ε-lys(α-nh2), agm, lys(oct) or ahx, at the c-terminus.

Methods for the in situ treatment of bone cancer


The present invention relates to methods for in situ treatment of malignant cells from a cancer associated with bone. In one method, the treatment is for a primary cancer and entails positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a site containing the malignant cells.

Methods for treating vascular leak syndrome


Disclosed are methods for treating vascular leak syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, inflammatory bowel disease.

Recombinant immunotoxin targeting mesothelin


Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents.

Methods for treating vascular leak syndrome


Disclosed are methods for treating vascular leak syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, irritable bowel disease.

Intracellular calcium modulation for cancer treatment


Tumor cells exhibit consistent abnormalities in calcium regulation. The present disclosure teaches methods by which such differences are exploited to induce apoptosis selectively in tumor/cancer cells while sparing normal cells.

Therapies for cancer using rlip76


The present invention is a composition identified as a region of rala binding protein 1, wherein the region neighbors a membrane-associated portion of the rala binding protein 1, reduces transport activity and membrane association of the rala binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells.

Methods and compositions to eliminate chronic lymphocytic leukemia and other hematologic malignant cells in stromal microenvironment for cancer therapy


The present invention regards compositions and methods for treating chronic lymphocytic leukemia in the in vivo tissue environment using selenium-containing compositions. In particular aspects, a selenium-comprising compound is administered to an individual wherein the cll cells are in a stromal cell environment, wherein stromal factors modulate the selenium comprising compound to enhance its activity..

Compositions and methods of use of phorbol esters


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like hiv and aids, or the development of neoplasms in a mammalian subject.

Anticancer therapeutic agents


The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (capcna) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy.. .

Methods for treating vascular leak syndrome


Disclosed are methods for treating vascular leak syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, irritable bowel disease.

Assay for colon and other cancers in humans


The present invention is concerned with a novel antigen associated with human tumors, including carcinomas of the colon, pancreas, and lung, as well as novel monoclonal antibodies which binds strongly to said antigen. The antibodies bind to normal human cells to a much lesser degree than to tumor cells.

System for detecting, actively targeting and selectively treating malignant cells in human body by non-invasive procedure


The embodiments herein provide a system and method for detecting, actively targeting and selectively treating the biological targets in a human body by a non-invasive procedure. The system comprises an electromagnetic inductor supported at a predetermined height and rotated to generate a high frequency magnetic field.

Diagnosing cancer using genomic sequencing


Methods, systems, and apparatus determine whether a first chromosomal region exhibits a deletion or an amplification associated with cancer in a sample from a subject (e.g., where the sample includes a mixture of cell-free dna from tumor cells and non-malignant cells. Nucleic acid molecules of the biological sample are sequenced.

Diagnostic tests using gene expression ratios


The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from cell or tissue samples, such as cancer cell or tissue samples. The invention also provides sets of genes that are expressed differentially in normal and cancer lung cells and tissues.

Use of tri-substituted glycerol compounds for the treatment of hematological malignancies


The present invention relates to the use of a tri-substituted glycerol compound for the manufacture of a medicament for the treatment of hematological malignancies. The invention also refers to a kit-of-parts comprising such a medicament.

Novel n- and c- terminal substituted antagonistic analogs of gh-rh


There is provided a novel series of synthetic analogs of hgh-rh(1-29)nh2 (seq id no: 96) and hgh-rh(1-30)nh2. Of particular interest are those carrying phac, n-me-aib, dca, ac-ada, fer, ac-amc, me-nh-sub, phac-ada, ac-ada-d-phe, ac-ada-phe, dca-ada, dca-amc, nac-ada, ada-ada, or ch3—(ch2)10—co-ada, at the n-terminus and β-ala, amc, apa, ada, ae2a, ae4p, ε-lys(α-nh2), agm, lys(oct) or ahx, at the c-terminus.

Targeting of cyp1b1 in the treatment of head and neck cancer and lung cancer


Methods for inhibiting the motility or proliferation of premalignant and malignant cells are provided. Methods for treating a malignancy of the head and neck and for treating a malignancy of the lung are also provided..

Oncolytic measles virus


The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein..

Methods for screening compounds for capability to inhibit premalignant squamous epithelial cell progression to a malignant state


Methods for screening compounds for their capability to inhibit cyp1b1-mediated proliferation and motility of and/or to reverse estrogen-induced reduction in apoptosis of premalignant or malignant cells are provided. Kits for practicing the screening methods are also provided..

Methods and compositions for treatment of hematologic cancers


The present invention relates to oncolytic picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed picornavirus such as coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto grafts prior to transplantation..

Methods of generating oligodendrocytes and cell populations comprising same


A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (mscs) with at least one exogenous mirna having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of seq id nos: 15-19 and 27-35, thereby generating the population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells.

Mammography-apparatus


Mammography-apparatus for detecting malignant cells in a breast comprising an x-ray source and an x-ray detector that cooperates with the x-ray source for providing an x-ray image of said breast, and further comprising a paddle for flattening the breast by pressing it against said x-ray detector, wherein at least one sensor is applied for measuring a parameter that is used for determining the pressure at which the paddle compresses the breast, and wherein a control system is provided which controls the actuation of the paddle depending on the pressure that is applied to the breast, wherein there is a contact area measuring unit for measuring the contact area between the breast and the paddle.. .



Malignant Cells topics:
  • Malignant Cells
  • Malignant Cell
  • Proliferation
  • Premalignant
  • Recombinant
  • Stem Cells
  • Endogenous
  • Malignancy
  • Proliferative Disorder
  • Antagonist
  • Amino Acid
  • Growth Hormone
  • Proliferative
  • Amino Acids
  • Lung Cancer


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Malignant Cells for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Malignant Cells with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.811

    2955

    1 - 1 - 58